Pharmaceuticals

Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients

SUZHOU, China, May 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the enrollment of ...

2023-05-03 08:00 5165

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment S...

2023-05-03 00:22 4250

Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...

2023-05-03 00:07 2806

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...

2023-05-02 17:30 5318

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged inCanada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for i...

2023-05-02 05:00 3326

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary ar...

2023-05-01 18:30 4151

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...

2023-05-01 08:58 3850

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health ...

2023-04-28 09:00 4572

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...

2023-04-28 00:29 4432

Fosun Collaborates with Non-profit Organizations to Provide "Chinese Solutions" to Jointly Build a Malaria-free World

HONG KONG, April 27, 2023 /PRNewswire/ -- A song spreads throughout the world from the Premier League fields; a seminar explores how civilian orgnanizations can carry out charitable activities for long-term effect inAfrica; and a charity "relay race" starts at Guilin,China, where artesunate was d...

2023-04-27 19:36 4173

BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ -- BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a$5.0m AUD grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to fund wor...

2023-04-27 12:15 2975

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announ...

2023-04-27 08:30 3811

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquireVienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medica...

2023-04-27 06:50 3628

RemeGen Celebrates World Intellectual Property Day 2023

YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, is celebrating World Intellectual Property Day 2023 which falls onApril 26, the theme of which mirrors the crit...

2023-04-26 10:00 3834

Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit

MIAMI and PERTH, Australia, April 26, 2023 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, establishes LumaCina business unit under Bridgewest Perth Pharma inPerth, Australia. The newly cre...

2023-04-26 06:41 2917

Bioved Pharmaceuticals granted a US Patent for its oral, natural plant-based product, Artovid-20® for the treatment of Covid-19

SAN JOSE, Calif., April 26, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is proud to announce that it has received a US Patent for its natural Ayurved based product, Artovid-20® Tablets for Covid-19. The Patent titled "Methods and Compounds for Treating Effects of Covid-19 Disease," grants 2...

2023-04-26 03:00 2394

IF YOU, A CHILD IN YOUR CARE, OR ANOTHER LOVED ONE WERE HARMED BY ENDO OR A RELATED COMPANY, INCLUDING PAR OR AMS, OR THEIR PRODUCTS INCLUDING OPIOIDS, RANITIDINE, OR TRANSVAGINAL MESH, YOUR RIGHTS MAY BE AFFECTED BY DEADLINES IN THE ENDO BANKRUPTCY.

The deadline to file a claim in the bankruptcy is July 7, 2023, at 5:00 p.m. (prevailing Eastern Time). The deadline to object to Endo's sale is July 7, 2023, at 4:00 p.m. (prevailing Eastern Time). NEW YORK, April 25, 2023 /PRNewswire/ -- The following is being issued by Kroll Restructuring Adm...

2023-04-25 22:27 2339

Nippon Express (UK) Receives IATA CEIV Pharma Certification for Its Facility in Heathrow Airport Suburb

TOKYO, April 25, 2023 /PRNewswire/ -- Nippon Express (UK) Ltd. (hereinafter "NXUK"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (I...

2023-04-25 15:00 3566

Biotech firm Gene Solutions: A promising picture for multi-cancer early detection in Southeast Asia

HO CHI MINH CITY, Vietnam, April 25, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions  published their research paper on Cancer Investigation:Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim r...

2023-04-25 12:00 3136

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal

SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged. On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evalu...

2023-04-24 14:53 3914
1 ... 113114115116117118119 ... 184